India Pharma Outlook Team | Saturday, 08 June 2024
During the BIO International Convention 2024 in San Diego, USA, the Department of Health – Abu Dhabi (DoH), the healthcare industry's regulator, and MSD, a top biopharmaceutical company, signed a Memorandum of Understanding (MoU). DoH and MSD hope to further cancer research by growing their long-standing relationship, with an emphasis on lung cancer clinical trials in Abu Dhabi.
The MoU was signed by Dr. Asma Ibrahim Al Mannaei, executive director of the DoH's Research and Innovation Centre, and Ashraf Mallak, managing director of MSD GCC, in the presence of H.E. Mansoor Ibrahim Al Mansoori, chairman of the Department of Health - Abu Dhabi (DoH) and Dr. Ernesto Munoz-Elias, AVP of Biology-Discovery at MSD Research Laboratories (MRL). This is the fourth partnership between the two organizations in just over two years, demonstrating their shared commitment to advancing healthcare and encouraging innovation in Abu Dhabi.
Dr. Asma Ibrahim Al Mannaei, Executive Director of the Research and Innovation Centre at the Department of Health – Abu Dhabi, said: “Reinforcing Abu Dhabi’s position as a leading destination for healthcare and life science, the Department of Health – Abu Dhabi is proud to build on the long-standing collaboration with our esteemed and strategic partners at MSD GCC. As we continue to face the complexities of healthcare challenges, DoH remains committed to leveraging the latest breakthroughs hand in hand with global partners to advance research and clinical trials which will ultimately drive innovation and improve healthcare outcomes.”